Welcome to our dedicated page for Atossa Therapeutics SEC filings (Ticker: ATOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Atossa Therapeutics, Inc. (Nasdaq: ATOS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Atossa’s clinical-stage biopharmaceutical operations, centered on the development of its investigational therapy (Z)-Endoxifen for oncology and other serious conditions.
Through forms such as Form 8-K, investors can review Atossa’s reports of material events, including quarterly financial result announcements, changes in executive leadership, regulatory strategy updates, and notices related to Nasdaq listing compliance. Recent 8-K filings describe financial results for specific quarters, the appointment of a new Chief Financial Officer, the release of an updated corporate presentation, and a notice from Nasdaq regarding the minimum bid price requirement and an extension of the compliance deadline.
Filings also document key regulatory and strategic steps, such as press releases incorporated by reference that outline Atossa’s plans for (Z)-Endoxifen in metastatic breast cancer, neoadjuvant ER+/HER2- disease, breast cancer risk reduction, and Rare Pediatric Disease designation for Duchenne Muscular Dystrophy. Additional materials may discuss intellectual property developments, including patents covering enteric oral formulations and methods of using (Z)-Endoxifen.
Stock Titan enhances these SEC filings with AI-powered summaries that aim to clarify the main points of lengthy documents, helping readers quickly identify items related to clinical programs, regulatory milestones, capital markets matters, and corporate governance. Users can also track insider and executive-related disclosures when reported in current reports or other SEC forms.
By reviewing Atossa’s SEC filings alongside AI-generated insights, investors and researchers can better understand the company’s risk factors, development priorities, financial condition, and the formal regulatory record supporting its (Z)-Endoxifen programs.
Atossa Therapeutics (ATOS) reported Q3 2025 results showing a net loss of
For the nine months, net loss was
As of
Atossa Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025 and providing a company update. The press release, dated November 12, 2025, is included as Exhibit 99.1 and incorporated by reference into this report. The company clarifies that the information in Items 2.02 and 9.01, including Exhibit 99.1, is being furnished rather than filed under securities law, which limits its use for certain liability provisions.
Atossa Therapeutics (ATOS) reported an insider equity award on Form 4. The company’s Chief Financial Officer received a stock option grant to purchase 578,000 shares at an exercise price of $1.03 per share, with a transaction date of October 14, 2025.
The options vest as follows: 25% on October 14, 2026, with the remaining 75% vesting in equal quarterly installments over the following three years, subject to continued service. The options expire on October 14, 2035. Ownership is listed as Direct.
Atossa Therapeutics (ATOS) filed a Form 3 initial statement of beneficial ownership for its Chief Financial Officer, Mark James Daniel, with a date of event of 10/14/2025. The filing states that no securities are beneficially owned. The submission includes an Exhibit 24 Power of Attorney and is filed by one reporting person.
Atossa Therapeutics (ATOS) appointed Mark Daniel as Chief Financial Officer and principal accounting officer, effective October 14, 2025, succeeding Heather Rees. Ms. Rees will remain as a non-officer employee through November 15, 2025 to assist the transition and will receive nine months of base salary and nine months of employer-paid COBRA under a separation agreement.
Mr. Daniel’s employment agreement includes a base salary of $415,900 and a target annual bonus of up to 40% of base salary beginning in fiscal 2026. He will receive an option to purchase 578,000 shares with an exercise price set at the grant-date close, vesting 25% on the first anniversary and the remainder in equal quarterly installments over three years. If terminated without Cause or for Good Reason (outside a change in control window), he is eligible for six months’ salary (50% of base) and up to six months of COBRA. Upon qualifying termination in connection with a change in control, benefits include a lump sum equal to 1.0x base salary plus target bonus, pro rata bonus, full equity acceleration, and up to twelve months of COBRA.
Atossa Therapeutics, Inc. reported that it has made an updated corporate presentation available as of September 26, 2025. The presentation is furnished as an exhibit to this report under a Regulation FD disclosure item, meaning it is intended to share information broadly with the market.
The company notes that this material is being furnished, not filed, so it is not subject to certain liability provisions of the federal securities laws and is not automatically incorporated into other SEC filings. The exhibit is identified as a corporate presentation dated September 26, 2025.
Atossa Therapeutics, Inc. filed a current report describing a strategic update. On September 8, 2025, the company announced a new regulatory strategy intended to accelerate development of its low-dose (Z)-endoxifen product candidate for breast cancer risk reduction. The company furnished a press release with further details as an exhibit to this report.
Atossa Therapeutics, Inc. notified Nasdaq that it was not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid of $1.00 for 30 consecutive business days. The company's initial compliance period ended on August 20, 2025, and after requesting an extension, Nasdaq granted a 180-day extension on August 21, 2025, moving the deadline to regain compliance to February 17, 2026.
Atossa Therapeutics reported widening losses as it advances clinical programs for its lead candidate, oral (Z)-endoxifen. For the six months ended June 30, 2025 the company recorded a $15.1 million net loss and used $13.2 million of cash in operations, compared with $11.9 million and $9.2 million a year earlier. Cash and cash equivalents totaled $57.9 million at June 30, 2025, with working capital of $55.7 million, and management expects this cash to fund operations for at least one year. Total operating expenses rose to $16.5 million for the six-month period driven by higher R&D spending on (Z)-endoxifen trials.
The company highlighted positive clinical signals: low-dose (Z)-endoxifen reduced mammographic breast density (1 mg: 17.3%, 2 mg: 23.5%, both p<0.01) and neoadjuvant and I-SPY 2 data showed tumor suppression and tolerability. Material items to monitor include pending PTAB proceedings challenging two patents (petitions filed by Intas), a non-cancellable clinical commitment of $7.9 million, and a Nasdaq notice requiring the company to regain a $1.00 bid compliance by August 20, 2025.
Atossa Therapeutics, Inc. reported on August 12, 2025 that it issued a press release announcing financial results for the quarter ended June 30, 2025 and providing a company update. The press release is attached as Exhibit 99.1 and the filing includes a cover page Interactive Data File as Exhibit 104. The Company states the information in Items 2.02 and 9.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or subject to certain Securities Act liabilities. This Current Report is signed by Heather Rees, Chief Financial Officer. No numerical financial metrics are included in the 8-K text provided here; consult Exhibit 99.1 for the detailed results and commentary.